Merrimack Pharmaceuticals, which uses its Network Biology system to discover and develop cancer treatments, postponed its IPO on Wednesday due to poor market conditions. The Cambridge, MA-based company was founded in 1993 and currently has five candidates in clinical programs. J.P. Morgan had been selected to lead manage the IPO.
